Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218770 · ClinicalTrials.gov registry record · Phase 1
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
A Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT07218770 is a Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 72 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07218770, a Phase 1 study of Active Noninfectious Uveitis Affecting the Posterior Segment, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG REGN7041
Study Locations (2)
Illinois
- Illinois Retina Associates - Oak Park
Tennessee
- Tennessee Retina PC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2028-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218770
The ClinicalTrials.gov registry entry for NCT07218770 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Noninfectious Uveitis Affecting the Posterior Segment appearing as the primary indexed condition, and to 1 intervention - of which REGN7041 is the first listed.
NCT07218770 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07218770 about?
NCT07218770 is a clinical study titled "A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants". This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the fir...
What is the current status of trial NCT07218770?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-12-17. Estimated completion is 2028-06-28.
What conditions does trial NCT07218770 study?
This clinical trial studies the following conditions: Active Noninfectious Uveitis Affecting the Posterior Segment.
What interventions are being tested in trial NCT07218770?
The interventions under investigation include: REGN7041 (DRUG).
Who is sponsoring clinical trial NCT07218770?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218770 being conducted?
This trial has 2 study locations across Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.